Adverse drug reactions with HER2-positive breast cancer treatment: an analysis from the Italian pharmacovigilance database
MA Barbieri, EE Sorbara, G Cicala, V Santoro… - Drugs-Real World …, 2022 - Springer
Background Anti-HER2 therapy has evolved in the last years and an important role in this
transformation was that of monoclonal antibodies and tyrosine kinase inhibitors …
transformation was that of monoclonal antibodies and tyrosine kinase inhibitors …
[HTML][HTML] Prognostic factors influencing progression-free survival in HER2-positive metastatic breast cancer patients who were treated with a combination of lapatinib …
Objective: The aim was to assess the prognostic variables in human epidermal growth factor
receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus …
receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus …
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
DT Chen, AN Saltos, T Rose, ZJ Thompson, R Thapa… - Cancers, 2023 - mdpi.com
Simple Summary This paper presents a paradigm-shifted approach for adverse event (AE)
analysis from classic descriptive summary into modern informative statistics to fulfill …
analysis from classic descriptive summary into modern informative statistics to fulfill …
Survival outcomes of nonsmall cell lung cancer patients treated with Afatinib who are affected by early adverse events
Introduction. Afatinib is a first‐line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …